Cary Street Partners Investment Advisory’s Intellia Therapeutics NTLA Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-600	Closed	-$19K	–	1408
2023 Q3	$19K	Hold	600	–	–	﹤0.01%	1143
2023 Q2	$24.5K	Hold	600	–	–	﹤0.01%	994
2023 Q1	$22.4K	Hold	600	–	–	﹤0.01%	944
2022 Q4	$20.9K	Buy	+600	New	+$28.5K	﹤0.01%	964

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cary Street Partners Investment Advisory's NTLA Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 600 shares — an estimated $19K sold.

Cary Street Partners Investment Advisory first reported a position in NTLA in Q4 2022 and held it in 4 quarters. The position peaked at $24.5K in Q2 2023. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 600 Intellia Therapeutics shares in Q4 2023, an estimated $19K.
Cary Street Partners Investment Advisory first reported a position in Intellia Therapeutics in Q4 2022 and held it in 4 quarters.
Cary Street Partners Investment Advisory's Intellia Therapeutics position peaked at $24.5K in Q2 2023.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.